Valuation: CSPC Pharmaceutical Group Limited

Market Cap 97.75B 12.46B 10.95B 10.18B 9.34B 17.55B 1,200B 17.82B 121B 47.23B 590B 46.79B 45.78B 2,040B P/E 2026 *
12x
P/E 2027 * 13.9x
Enterprise Value 87.11B 11.11B 9.76B 9.07B 8.33B 15.64B 1,070B 15.88B 108B 42.09B 526B 41.7B 40.8B 1,818B EV / Sales 2026 *
2.45x
EV / Sales 2027 * 2.39x
Free-Float
67.42%
Yield 2026 *
4.25%
Yield 2027 * 4.31%
Jul. 24 CSPC Pharmaceutical Group Limited Announces Marketing Approval For Paliperidone Palmitate Injection CI
Jul. 22 CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial of Sys6026 Injection for HPV Type 16 or 18 Related Cervical High Grade Squamous Intraepithelial Lesion in China CI
Jul. 17 CSPC Pharmaceutical Group Limited Announces New Drug Application for Trastuzumab Envedotin Injection Accepted by Nmpa CI
Jul. 17 CSPC Pharma's Application for Breast Cancer Drug Candidate Accepted in China MT
Jul. 16 CSPC Pharma Begins Two Drug Trials in China MT
Jul. 15 CSPC Pharma's Breast Cancer Drug Combination Granted China Breakthrough Designation MT
Jul. 14 CSPC Pharmaceutical Group Limited Announces Docetaxel for Injection (Albumin-Bound) and Anbenitamab Receives Breakthrough Therapy Designation in China for First-Line Treatment of Advanced HER2-Positive Breast Cancer Co-Developed by Shanghai JMT-BIO Technology Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd CI
Jul. 07 Weight-loss drug developers line up to tap lucrative market as competition heats up RE
Jul. 07 CSPC Pharma Begins Phase II Trial of Mixed Hyperlipidaemia Drug MT
Jul. 07 CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial Of SYH2070 Injection For Treatment Of Mixed Hyperlipidaemia At First Centre In China CI
Jul. 02 European Stocks Surge, Oil Prices Drop; Defense, Luxury Shares Rally MT
Jul. 02 CSPC Pharma Begins Tumor Drug Trial in China MT
Jul. 02 AstraZeneca Collaborating With CSPC Pharma in siRNA Drug Deal Worth Up to $1.77 Billion MT
1 day+2.15%
1 week+5.56%
Current month+22.67%
1 month+25.92%
3 months-4.79%
6 months-12.84%
Current year+1.42%
1 week 8.12
Extreme 8.12
8.86
1 month 6.59
Extreme 6.59
8.86
Current year 6.53
Extreme 6.53
10.96
1 year 6.53
Extreme 6.53
11.63
3 years 4.27
Extreme 4.27
11.63
5 years 4.27
Extreme 4.27
11.9
10 years 3.47
Extreme 3.4687
13.93
Manager TitleAgeSince
Chief Executive Officer 46 2025-12-18
Chief Operating Officer 56 2025-12-18
Corporate Officer/Principal 47 2004-06-30
Director TitleAgeSince
Chairman 72 2011-08-25
Director/Board Member 66 2012-12-20
Director/Board Member 56 2025-12-18
Date Insider Type Main position Quantity % Market Cap.
6/23/26 Other

Chief Operating Officer

-1,400,000 0.0122%
6/23/26 Other

Director

-700,000 0.0061%
6/22/26 Other

Chairman

14,650,000 0.1271%
Change 5-day change 1-year change 3-year change Capi.($)
+2.15%+5.56%-0.81%+36.36% 12.46B
+0.86%+1.43%+48.50%+160.39% 1,067B
+1.59%+4.09%+55.34%+53.96% 635B
+0.95%+1.91%+35.91%+81.14% 458B
+1.60%+6.25%+33.95%+29.84% 347B
-0.60%+1.52%+35.68%+39.76% 295B
-0.14%+0.60%+16.17%+17.53% 262B
+0.09%-2.82%-28.29%-41.71% 216B
+1.22%+2.66%+21.87%+59.73% 203B
-1.18%-3.70%+14.23%+66.51% 161B
Average +0.55%+1.75%+23.26%+50.35% 365.55B
Weighted average by Cap. +0.55%+1.96%+35.69%+77.53%

Financials

2026 *2027 *
Net sales 35.57B 4.54B 3.98B 3.71B 3.4B 6.39B 437B 6.49B 44B 17.19B 215B 17.03B 16.66B 743B 35.13B 4.48B 3.93B 3.66B 3.36B 6.31B 431B 6.41B 43.45B 16.98B 212B 16.82B 16.46B 733B
Net income 7.86B 1B 881M 819M 752M 1.41B 96.57B 1.43B 9.73B 3.8B 47.48B 3.76B 3.68B 164B 6.92B 882M 775M 721M 661M 1.24B 84.98B 1.26B 8.56B 3.34B 41.78B 3.31B 3.24B 144B
Net Debt -10.64B -1.36B -1.19B -1.11B -1.02B -1.91B -131B -1.94B -13.16B -5.14B -64.24B -5.09B -4.98B -222B -13.75B -1.75B -1.54B -1.43B -1.31B -2.47B -169B -2.51B -17.01B -6.64B -83.01B -6.58B -6.44B -287B
Logo CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.
Employees
19,700
Date Price Change Volume
26-07-24 HK$8.550 +2.15% 136,279,490
26-07-23 HK$8.370 -0.36% 29,576,730
26-07-22 HK$8.400 -0.12% 65,282,728
26-07-21 HK$8.410 -1.06% 56,858,983
26-07-20 HK$8.500 +4.94% 85,944,318
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
8.550HKD
Average target price
11.47HKD
Spread / Average Target
+34.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 1093 Stock